Abstract: HJ Science, a China-based clinical-stage biotech company, has passed the hearing for a Hong Kong Chapter 18A listing. CITIC Securities is the sole sponsor. In this note, we look at the company's core products HJ787, HJ178, and HJ891, and key product HJ197. We also look at the company's business development, pre-IPO investors, and management team.
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.